Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 4
2007 2
2008 1
2009 3
2010 4
2011 5
2012 2
2013 1
2015 2
2016 2
2017 5
2018 2
2019 4
2020 1
2021 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Pertuzumab for the treatment of breast cancer.
Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M. Robert M, et al. Among authors: bourbouloux e. Expert Rev Anticancer Ther. 2020 Feb;20(2):85-95. doi: 10.1080/14737140.2019.1596805. Epub 2019 Aug 29. Expert Rev Anticancer Ther. 2020. PMID: 30884986 Review.
Evaluating everolimus for the treatment of breast cancer.
Moreau-Bachelard C, Robert M, Gourmelon C, Bourbouloux E, Patsouris A, Frenel JS, Campone M. Moreau-Bachelard C, et al. Among authors: bourbouloux e. Expert Opin Pharmacother. 2023 May-Aug;24(10):1105-1111. doi: 10.1080/14656566.2023.2214677. Epub 2023 May 18. Expert Opin Pharmacother. 2023. PMID: 37183684 Review.
Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.
Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M. Robert M, et al. Among authors: bourbouloux e. Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):85-91. doi: 10.1080/17425255.2019.1559816. Epub 2019 Jan 5. Expert Opin Drug Metab Toxicol. 2019. PMID: 30577708 Review.
Lapatinib in metastatic breast cancer.
Frenel JS, Bourbouloux E, Berton-Rigaud D, Sadot-Lebouvier S, Zanetti A, Campone M. Frenel JS, et al. Among authors: bourbouloux e. Womens Health (Lond). 2009 Nov;5(6):603-12. doi: 10.2217/whe.09.54. Womens Health (Lond). 2009. PMID: 19863462 Free article. Review.
An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Robert M, Frenel JS, Bourbouloux E, Rigaud DB, Patsouris A, Augereau P, Gourmelon C, Campone M. Robert M, et al. Among authors: bourbouloux e. Drugs. 2018 Sep;78(13):1353-1362. doi: 10.1007/s40265-018-0972-9. Drugs. 2018. PMID: 30143968 Review.
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
Augereau P, Patsouris A, Bourbouloux E, Gourmelon C, Abadie Lacourtoisie S, Berton Rigaud D, Soulié P, Frenel JS, Campone M. Augereau P, et al. Among authors: bourbouloux e. Ther Adv Med Oncol. 2017 May;9(5):335-346. doi: 10.1177/1758834017693195. Epub 2017 Mar 14. Ther Adv Med Oncol. 2017. PMID: 28529550 Free PMC article. Review.
Benefits versus risk profile of buparlisib for the treatment of breast cancer.
Patsouris A, Augereau P, Frenel JS, Robert M, Gourmelon C, Bourbouloux E, Berton-Rigaud D, Chevalier LM, Campone M. Patsouris A, et al. Among authors: bourbouloux e. Expert Opin Drug Saf. 2019 Jul;18(7):553-562. doi: 10.1080/14740338.2019.1623877. Expert Opin Drug Saf. 2019. PMID: 31159599 Review.
[Her2 positive breast cancer: practices].
Campone M, Berton-Rigaud D, Bourbouloux E, Sophie S, Zanetti A, Frenel JS. Campone M, et al. Among authors: bourbouloux e. Bull Cancer. 2011 Feb;98(2):154-63. Bull Cancer. 2011. PMID: 21591301 Free article. Review. French.
Taxanes in adjuvant breast cancer setting: which standard in Europe?
Campone M, Fumoleau P, Bourbouloux E, Kerbrat P, Roché H. Campone M, et al. Among authors: bourbouloux e. Crit Rev Oncol Hematol. 2005 Sep;55(3):167-75. doi: 10.1016/j.critrevonc.2005.04.003. Crit Rev Oncol Hematol. 2005. PMID: 16039867 Review.
38 results